CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Cancer Cell

• Publication date

  2014-11-10

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.ccell.2014.10.008PMID 25517740
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy

  2014cited by this paper
• Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity.

  2014influential reference
• CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy.

  2014cited by this paper
• Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

  2014influential reference
• Immunogenic cell death in cancer therapy.

  2013cited by this paper
• Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells.

  2013cited by this paper
• Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance.

  2013cited by this paper
• The immune contexture in human tumours: impact on clinical outcome

  2012cited by this paper
• Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors

  2009cited by this paper
• Batf3 Deficiency Reveals a Critical Role for CD8α+ Dendritic Cells in Cytotoxic T Cell Immunity

  2008cited by this paper

• Aptamer-Engineered Liposomal Platform Enables in Situ cDC1 Vaccination to Potentiate Immunotherapy in Prostate Cancer.

  2026cites this paper
• The potential application of stroma modulation in targeting tumor cells: focus on pancreatic cancer and breast cancer models.

  2025cites this paper
• The antitumor mechanism of immuno-flap treatment in a rat model of head and neck cancer

  2025cites this paper
• A Tc1‐ and Th1‐T‐lymphocyte‐rich tumor microenvironment is a hallmark of MSI colorectal cancer

  2025cites this paper
• Hypothesis of a CD137/Eomes activating axis for effector T cells in HPV oropharyngeal cancers

  2024cites this paper
• From promise to progress: the dynamic landscape of glioblastoma immunotherapy.

  2024cites this paper
• Tumor immunity: A brief overview of tumor‑infiltrating immune cells and research advances into tumor‑infiltrating lymphocytes in gynecological malignancies (Review)

  2024cites this paper
• TIM-3 increases the abundance of type-2 dendritic cells during Leishmania donovani infection by enhancing IL-10 production via STAT3

  2023cites this paper
• Conventional type 1 dendritic cells (cDC1) in cancer immunity

  2023cites this paper
• mRNAs encoding IL-12 and a decoy-resistant variant of IL-18 synergize to engineer T cells for efficacious intratumoral adoptive immunotherapy

  2023cites this paper
• A therapeutic DC vaccine with maintained immunological activity exhibits robust anti-tumor efficacy.

  2022cites this paper
• An oral WT1 protein vaccine composed of WT1-anchored, genetically engineered Bifidobacterium longum allows for intestinal immunity in mice with acute myeloid leukemia

  2022cites this paper
• Dual Effect of Immune Cells within Tumour Microenvironment: Pro- and Anti-Tumour Effects and Their Triggers

  2022cites this paper
• Reactivation of dysfunctional dendritic cells by a stress-relieving nanosystem resets anti-tumor immune landscape

  2022cites this paper
• Formulation of a recombinant HIV‐1 polytope candidate vaccine with naloxone/alum mixture: induction of multi‐cytokine responses with a higher regulatory mechanism

  2021cites this paper
• Trial watch: TLR3 agonists in cancer therapy

  2020cites this paper
• Dendritic Cells in the Tumor Microenvironment.

  2020cites this paper
• The helminth-derived peptide GK-1 induces an anti-tumoral CD8 T cell response associated with downregulation of the PD-1/PD-L1 pathway.

  2020cites this paper
• CSF1R methylation is a key regulatory mechanism of tumor-associated macrophages in hepatocellular carcinoma

  2020influential citation
• Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

  2020cites this paper
• Intratumoral delivery of tavokinogene telseplasmid yields systemic immune responses in metastatic melanoma patients.

  2020cites this paper
• Dendritic cell biology and its role in tumor immunotherapy

  2020cites this paper
• Intratumor Adoptive Transfer of IL-12 mRNA Transiently Engineered Antitumor CD8+ T Cells.

  2019cites this paper
• CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function

  2019cites this paper
• CD103+ T and Dendritic Cells Indicate a Favorable Prognosis in Oral Cancer

  2019cites this paper
• Synergistic cancer immunotherapy combines MVA-CD40L induced innate and adaptive immunity with tumor targeting antibodies

  2019cites this paper
• Cancer Stem Cells (CSCs) and Their Application in Cancer Immunotherapy

  2018cites this paper
• Anti-CD137 Suppresses Tumor Growth by Blocking Reverse Signaling by CD137 Ligand.

  2017cites this paper
• Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response

  2017cites this paper
• Immunoplasticity in cutaneous melanoma: beyond pure morphology

  2017cites this paper
• Impact of IL-12 in Cancer.

  2017cites this paper
• Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis

  2017cites this paper
• Antigen‐presenting dendritic cells in atherosclerosis

  2017cites this paper
• Intratumoral Delivery of Immunotherapy—Act Locally, Think Globally

  2017cites this paper
• Deletion of Batf3-dependent antigen-presenting cells does not affect atherosclerotic lesion formation in mice

  2017cites this paper
• A Comparative Study of Replication-Incompetent and -Competent Adenoviral Therapy-Mediated Immune Response in a Murine Glioma Model

  2017cites this paper
• Plasma cells in primary melanoma. Prognostic significance and possible role of IgA

  2016cites this paper
• The role of TLR2 activation in promoting tumor dendritic cell dysfunction

  2016cites this paper
• Advances in immunotherapy for the treatment of glioblastoma

  2016cites this paper
• Strong inflammatory response and Th1-polarization profile in children with acute lymphoblastic leukemia without apparent infection.

  2016cites this paper
• Biphasic function of TLR3 adjuvant on tumor and spleen dendritic cells promotes tumor T cell infiltration and regression in a vaccine therapy

  2016cites this paper
• The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

  2015cites this paper
• The transduction pattern of IL‐12‐encoding lentiviral vectors shapes the immunological outcome

  2015cites this paper
• Toll-like Receptor 2 Activation Promotes Tumor Dendritic Cell Dysfunction by Regulating IL-6 and IL-10 Receptor Signaling.

  2015cites this paper